Anti-tumor efficacy of human anti-c-met CAR-T cells against papillary renal cell carcinoma in an orthotopic model

Cancer Sci. 2021 Apr;112(4):1417-1428. doi: 10.1111/cas.14835. Epub 2021 Feb 24.

Abstract

Chimeric antigen receptor (CAR)-T cell therapy has shown salient efficacy in cancer immunotherapy, particularly in the treatment of B cell malignancies. However, the efficacy of CAR-T for solid tumors remains inadequate. In this study, we displayed that c-met is an appropriate therapeutic target for papillary renal cell carcinoma (PRCC) using clinical samples, developed an anti-human c-met CAR-T cells, and investigated the anti-tumor efficacy of the CAR-T cells using an orthotopic mouse model as pre-clinical research. Administration of the anti-c-met CAR-T cells induced marked infiltration of the CAR-T cells into the tumor tissue and unambiguous suppression of tumor growth. Furthermore, in combination with axitinib, the anti-tumor efficacy of the CAR-T cells was synergistically augmented. Taken together, our current study demonstrated the potential for clinical application of anti-c-met CAR-T cells in the treatment of patients with PRCC.

Keywords: CAR-T cells; axitinib; c-met; orthotopic model; papillary renal cell carcinoma.

MeSH terms

  • Aged
  • Animals
  • Antibodies / immunology
  • Antigens, Neoplasm / immunology
  • Carcinoma, Renal Cell / immunology*
  • Carcinoma, Renal Cell / therapy*
  • Cell Line, Tumor
  • Cells, Cultured
  • Disease Models, Animal
  • Female
  • Humans
  • Immunotherapy / methods
  • Kidney Neoplasms / immunology*
  • Kidney Neoplasms / therapy*
  • Male
  • Mice
  • Mice, Inbred NOD
  • Proto-Oncogene Proteins c-met / immunology*
  • Receptors, Chimeric Antigen / immunology*
  • T-Lymphocytes / immunology*
  • Xenograft Model Antitumor Assays / methods

Substances

  • Antibodies
  • Antigens, Neoplasm
  • Receptors, Chimeric Antigen
  • MET protein, human
  • Proto-Oncogene Proteins c-met